Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.43) by 75.64 percent. This is a 27.12 percent decrease over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $15.288 million which missed the analyst consensus estimate of $36.664 million by 58.30 percent.